Wanbury Ltd

Wanbury Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed below reflect the company’s current position as of 09 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a sharp 12.9% drop in the stock price on 2 Jun 2026, the company’s longer-term performance continues to outpace the broader market, though recent technical indicators suggest a cautious stance for investors.

At Rs 315.20, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Wanbury Ltd locked at its upper circuit of 3.23% on 29 May 2026, with buyers queuing and no sellers willing to part with shares.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Hold to Buy as of 27 May 2026. This change reflects significant improvements across valuation, financial trends, quality metrics, and technical indicators, signalling renewed investor confidence in the company’s growth prospects and market positioning.

At Rs 300.20, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Wanbury Ltd locked at its upper circuit of 5% on 27 May 2026, with buyers queuing and no sellers willing to part with shares.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from a fair to an attractive rating. This change reflects evolving market perceptions amid a challenging industry backdrop, with the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now presenting a more compelling investment case relative to peers and historical averages.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold following a reassessment of its valuation and technical indicators. Despite robust financial performance and strong long-term returns, concerns over valuation metrics and promoter share pledging have tempered enthusiasm among analysts.

At Rs 268.85, sellers were still queuing — but there were no buyers willing to take the other side. Wanbury Ltd locked at its lower circuit of 5% on 21 May 2026, with unfilled sell orders and a frozen price, reflecting persistent selling pressure in a micro-cap stock.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a fair rating. This change comes amid a backdrop of strong operational metrics and a mixed valuation landscape within its peer group, prompting investors to reassess the stock’s price attractiveness relative to historical and sector benchmarks.

At Rs 271, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Wanbury Ltd locked at its upper circuit of 5% on 20 May 2026, with buyers queuing and no sellers willing to part with shares.

Wanbury Ltd has seen its investment rating upgraded from Hold to Buy, reflecting significant improvements across multiple key parameters including quality, valuation, financial trends, and technical indicators. This upgrade, effective from 19 May 2026, is underpinned by robust quarterly financial performance, attractive valuation metrics, and a bullish technical outlook, positioning the pharmaceutical micro-cap favourably amid sector peers.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, upgrading its outlook from mildly bullish to bullish. This change is underscored by a combination of positive signals from key technical indicators including MACD, Bollinger Bands, and moving averages, suggesting renewed investor interest and potential upside in the near term.

At Rs 261.55, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Wanbury Ltd locked at its upper circuit of 5.0% on 12 May 2026, with buyers queuing and no sellers willing to part with shares.

Wanbury Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 28 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 May 2026, providing investors with an up-to-date view of the company's performance and outlook.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 28 Apr 2026. This adjustment reflects a nuanced assessment across four key parameters: quality, valuation, financial trend, and technicals. While the company continues to demonstrate robust financial performance and attractive valuation metrics, evolving technical indicators and certain risk factors have prompted a more cautious stance.